Kilambi News
Wednesday, November 18, 2026

FDA grants accelerated approval to GSK lung cancer drug Nelkarmi

Life Sciences Tuesday, November 17, 2026 - Updated Nov 17, 2026 14:22

The US Food and Drug Administration on Tuesday granted accelerated approval to GSK's neladalkib, sold as Nelkarmi, for a rare form of advanced lung cancer in patients whose disease has progressed on existing targeted drugs.

Why it matters: Nelkarmi is the second lung cancer approval from GSK's $10.6 billion acquisition of Nuvalent, the centrepiece of the company's return to oncology, and it enters a market led by Roche's Alecensa and Pfizer's Lorbrena.

Data as of Reuters report of November 17, 2026, read in full via KTWB syndication; the FDA's own approval notice and a GSK release had not been obtained when this item was written, so the approval terms are reported as Reuters states them. Developing item.

The US Food and Drug Administration on Tuesday granted accelerated approval to GSK’s therapy for a rare form of advanced lung cancer in patients whose disease has worsened on existing drugs, Reuters reported. The once daily oral therapy, neladalkib, sold under the brand name Nelkarmi, is approved for patients with a type of non-small cell lung cancer whose disease has progressed after treatment with ALK tyrosine kinase inhibitors, a class of targeted drugs that block an abnormal protein driving tumour growth.

Neladalkib was one of two late stage lung cancer drugs GSK gained through its $10.6 billion acquisition of Nuvalent, completed in July; the other, Jideytro, won FDA approval the same month. The application rested on a trial in which the drug shrank tumours, including tumours that had spread to the brain, in previously treated patients, and the drug is also being studied against Roche’s Alecensa as a first line treatment in a late stage trial.

Sources

  1. US FDA approves GSK's second lung cancer drug from historic Nuvalent deal - Reuters, via KTWB - 2026-11-17